In this role, he initiated further extensive restructuring measures, divesting various organizational units and strengthening the company's core business by means of targeted acquisitions, including the purchase in 2006 of the laboratory consumables supplier Fisher Scientific.
[6] On 3 June 2014 Bayer AG announced that its Supervisory Board had extended Marijn Dekkers' term as CEO by two years, on expiration of the initial five-year period.
[9] In 2017 Dekkers founded Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry (www.novalislifesciences.com).
"Manager of the Year 2014" by German business magazine "Manager Magazin" [10] "Business person of the Year 2015" by the "Finanzen Verlag" publishing group and the readers of its publications "€uro am Sonntag", "€uro" and "Börse online" [11] "Most Innovative CEO International 2015" by the German industry's "Innovation Award" [12] In 2013 some controversy was sparked during a Financial Times panel discussion with relation to Bayer's kidney and liver cancer drug Nexavar.
"[16][17][18]Médecins Sans Frontières responded to Dekkers' comment, saying that it sums up everything that is wrong with the multinational pharmaceutical industry.
[19] Dekkers replied to this, referring to the decision made by the Indian government, not to protect a patent on Nexavar and the intellectual property of Bayer.